Nanoprecipitation preparation of low temperature-sensitive magnetoliposomes

Cheung, C. C. L., Monaco, I., Kostevšek, N., & Al-Jamal, W. T. (2020). Nanoprecipitation preparation of low temperature-sensitive magnetoliposomes. *COLLOIDS AND SURFACES B-BIOINTERFACES*, 111453. <https://doi.org/10.1016/j.colsurfb.2020.111453>

Published in:
COLLOIDS AND SURFACES B-BIOINTERFACES

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2020 Elsevier.

This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Nanoprecipitation preparation of low temperature-sensitive magnetoliposomes

5 *Calvin C.L. Cheung*^a, *Ilaria Monaco*^b, *Nina Kostevšek*^c, *Mauro Comes Franchini*^b, and
 Wafa T. Al-Jamal^{a*}

^a School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom

^b Department of Industrial Chemistry "Toso Montanari", University of Bologna, Italy

^c Department for Nanostructured Materials, Jožef Stefan Institute, Ljubljana, Slovenia

10

*Corresponding author:

Dr Wafa' T. Al-Jamal

School of Pharmacy

Queen's University Belfast

15 Belfast, BT9 7BL

United Kingdom

E-mail: w.al-jamal@qub.ac.uk

Abstract

20 Lysolipid-containing thermosensitive liposomes (LTSL) have gained attention for triggered
release of chemotherapeutics. Superparamagnetic iron oxide nanoparticles (SPION) offers
multimodal imaging and hyperthermia therapy opportunities as a promising theranostic agent.
Combining LTSL with SPION may further enhance their performance and functionality of
LTSL. However, a major challenge in clinical translation of nanomedicine is the poor
25 scalability and complexity of their preparation process. Exploiting the nature of self-assembly,
nanoprecipitation is a simple and scalable technique for preparing liposomes. Herein, we
developed a novel SPION-incorporated lysolipid-containing thermosensitive liposome
(mLTSL10) formulation using nanoprecipitation. The formulation and processing parameters
were carefully designed to ensure high reproducibility and stability of mLTSL10. The effect of
30 solvent, aqueous-to-organic volume ratio, SPION concentration on the mLTSL10 size and
dispersity was investigated. mLTSL10 were successfully prepared with a small size (~100 nm),
phase transition temperature at around 42 °C, and high doxorubicin encapsulation efficiency.
Indifferent from blank LTSL, we demonstrated that mLTSL10 combining the functionality of
both LTSL and SPION can be successfully prepared using a scalable nanoprecipitation
35 approach.

1 Introduction

Lysolipid-containing thermosensitive liposomes (LTSL) have been developed as a promising solution to enhance tumor drug bioavailability, in contrast to conventional liposomal formulations that rely on passive release [1]. LTSL comprises base phospholipid 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), lysolipid 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (MSPC), and PEG-lipid 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000). Lysolipids participate in the stabilization of membrane pores during phase transition, allowing burst release of entrapped hydrophilic drug; while PEG-lipids provide interfacial stabilizing (stealth) effect to prolong blood circulation and also facilitate drug release [2]. The most clinically advanced LTSL is ThermoDox®, a LTSL formulation optimized for the burst release of doxorubicin upon applying mild hyperthermia (40 – 42 °C). To date, it is the first and only thermosensitive liposomal formulation to reach clinical trials, evaluating the treatment of solid tumors in combination with radiofrequency ablation and mild hyperthermia [3].

Additional modalities have been included in the LTSL platform to monitor and improve the performance of drug release. Metallic nanoparticles, such as superparamagnetic iron oxide nanoparticles (SPION) [4], gold nanoparticles [4,5] and copper sulfide nanoparticles [6], offer attractive optical and magnetic properties. They have been incorporated into LTSL as liposome-nanoparticle hybrids, for potential non-invasive bioimaging modality and trigger release controlled through external stimuli [4]. SPION-loaded liposomes, or magnetoliposomes, are particularly attractive for their promising multifunctionality. Magnetoliposomes enable magnetic targeted drug delivery [7,8], and act as an efficient MRI contrast agent with enhancing T_2 contrast, for image-guided drug delivery applications [9]. Once they reached the targeted site, the embedded SPION can generate heat when exposed to external stimuli, such as near-infrared laser irradiation or alternative magnetic field, thus

heating up lipid bilayer and trigger drug release [10,11]. Consequently, drug release can be controlled spatially and temporally. Moreover, magnetic hyperthermia treatment can trigger cell death by promoting apoptosis and necrosis or even via thermal ablation [12,13].

65 Furthermore, the incorporation of SPION have been reported to stabilize the lipid bilayer and reduces unfavorable premature drug leakage from liposomes [14].

Despite the promising potentials of magnetoliposomes, their clinical translation has been slow; a significant hurdle in nanomedicines translation besides safety, is the complexity in scaling up laborious manufacturing processes. To date, most of the magnetoliposome formulations
70 utilized conventional batch methods, namely reverse phase evaporation or lipid film hydration, combined with sonication or extrusion. These are cumbersome bench-scale techniques, which are challenging to scale up and come along with other issues including low production yield, poor batch-to-batch reproducibility and cost ineffectiveness [15]. To date, reports on the scalable preparation of magnetoliposomes have been lacking. In this regard, nanoprecipitation
75 is a scalable approach that enables the formation of liposomes in one-step via self-assembly, without the need to homogenize vesicles size [16,17]. Briefly, a water-miscible organic solution of lipids (and SPION) is mixed with an aqueous solution, where lipid molecules self-assemble into liposomes spontaneously as they become less soluble in the aqueous non-solvent phase. Liposome sizes are controlled simply by adjusting the formulation and processing
80 parameters, abolishing the need of downsizing and homogenization [18]. Owing to the nature of self-assembly, prepared liposomes have narrow size distribution and high reproducibility [19]. Moreover, nanoprecipitation of liposomes can be made continuous with the help of microfluidics. Microfluidics, the manipulation of fluid in microscale channels, have drawn much attention in recent years for the production of liposomes in a well-controlled,
85 reproducible and high-throughput manner [20].

We have shown previously the optimized preparation of LTSL and the entrapment of a hydrophobic drug using the microfluidics nanoprecipitation approach [21]. Herein, this work demonstrates for the first time the preparation of SPION-loaded LTSL (mLTSL) using nanoprecipitation. We have demonstrated the successful preparation and characterization of
90 homogeneous, nano-sized (100 and 200 nm) SPION-loaded LTSL, with hydrophilic drug loading capability.

2 Materials and methods

2.1 Materials

95 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) were generous gifts from Lipoid GmbH (Ludwigshafen, Germany). 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (MSPC) was purchased from Avanti Polar Lipids (AL, US). Doxorubicin hydrochloride (DOX) was purchased from Apollo Scientific (Cheshire, UK).
100 Ammonium sulfate ((NH₄)₂SO₄), ethanol, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), sodium chloride (NaCl), tetrahydrofuran, Triton™ X-100 were purchased from Sigma-Aldrich (Dorset, UK). Nitric acid for trace analysis was purchased from VWR (Leicestershire, UK).

2.2 Preparation of N-palmitoyl-6-nitrodopamine-coated iron oxide nanoparticles

105 Hydrophobic N-palmitoyl-6-nitrodopamine (PNDA)-coated superparamagnetic iron oxide nanoparticles (SPION) was synthesized and characterized as we reported previously [22]. Briefly, oleic acid (OA)-coated SPION was first synthesized by thermal decomposition of iron pentacarbonyl in octyl ether in the presence of oleic acid as described in the literature [23]. PNDA ligand was synthesized as described in the literature [24]. OA-coated SPION was ligand
110 exchanged to PNDA to obtain PNDA-coated SPION, where a solution of 20 mg mL⁻¹ PNDA in THF/DMSO (2/1, v/v) was added dropwise to a solution of 3 mg mL⁻¹ OA-coated SPION in THF. The mixture was stirred at 50 °C for 24 h, then washed by THF and centrifuged for 1 h at 10000 g three times. The resultant PNDA-coated SPION (hereinafter called SPION) were dispersed in THF and stored at 4 °C. The mean diameter of SPION was 4.5 nm, characterized
115 by transmission electron microscopy analysis; PNDA-coating was characterized and confirmed

by Fourier-transform infrared spectroscopy; magnetic properties of SPION was measured by vibrating-sample magnetometry and superparamagnetism was confirmed [22].

2.3 Preparation of SPION-loaded LTSL (mLTSL10)

A mixture of SPION and 10 mM LTSL10 (DPPC/MSPC/DSPE-PEG₂₀₀₀, 80/10/10 molar ratio) was prepared by dissolving 8 μ mol DPPC (5.87 mg), 1 μ mol MSPC (0.52 mg), 1 μ mol DSPE-PEG₂₀₀₀ (2.79 mg) and 0 - 400 μ g SPION, per mL of THF/ethanol (1/1, v/v; unless otherwise stated). Typically, 0.5 mL of the lipid mixture and (NH₄)₂SO₄ solution (240 mM (NH₄)₂SO₄, pH 5.4) were preheated to 60 °C in a water bath. The volume of (NH₄)₂SO₄ used depends on the designated aqueous-to-organic volume ratio. The lipid mixture was withdrawn and rapidly injected into the (NH₄)₂SO₄ solution, and mixed until viscous fingering was no longer visible. The formed liposomes were annealed at 60 °C for 1.5 h. Annealed liposomes were purified and buffer exchanged to HEPES-buffered saline (HBS; 20 mM HEPES, 137 mM NaCl, pH 7.4) by size-exclusion chromatography (SEC) using Sephadex G-25 in PD-10 desalting column.

2.4 Particle size distribution analysis by dynamic light scattering (DLS)

Z-average diameter and dispersity were determined using Zetasizer Nano ZS90 (Malvern Panalytical, Worcestershire, UK) equipped with a 4.0 mW He-Ne laser operating at 633 nm with photodiode detector at a detection angle at 90°. Liposomal samples were diluted 10-fold in DW and transferred to low-volume polystyrene cuvettes. Z-average and dispersity of each sample were obtained as the mean of three measurements. The term “dispersity” is used instead of “polydispersity index”, in accordance with recommendations of IUPAC [25].

2.5 Atomic absorption spectroscopy (AAS)

Total concentrations of iron content of samples were determined by atomic absorption spectroscopy (AAS) using an Agilent 55 AA (Agilent, CA, US) equipped with Lumina hollow cathode lamp (PerkinElmer, UK). Iron absorbance was measured at absorption wavelength of

140 248.33 nm. The system was blanked by deionized water, calibrated standards were prepared by diluting an iron standard solution (Sigma, UK) to 1, 2 and 5 ppm ($\mu\text{g mL}^{-1}$). Recalibration was performed between every ten samples. Samples were first completely dried off using a block heater, then 1 mL of concentrated nitric acid was added and heated at 80 °C for 2 h for acid digestion. Digested samples were diluted appropriately by deionized water and filtered
145 through a 0.45 μm syringe filter before AAS measurement.

2.6 Differential scanning calorimetry (DSC)

Thermograms were recorded on TA Q200 DSC (TA Instruments, DE, US), in the temperature range of 35 – 50 °C with a heating rate of 1 °C min^{-1} . Purified mLTSL10 samples were concentrated by centrifugation to lipid concentration of 10 mM lipid. 20 μL of samples and
150 HBS reference were transferred to two respective DSC pans and sealed with DSC hermetic lids (TA Instruments, DE, US).

2.7 Transmission electron microscopy (TEM)

TEM micrographs were imaged using a JEOL JEM-1400 Plus transmission electron microscope, operating at an accelerating voltage of 120 kV. Purified mLTSL10 samples were
155 diluted 100 times by deionized water; 2.5 μL of sample was added on a carbon-coated 400 mesh copper grid (Ted Pella, Inc., Redding, CA, US) and allowed to air-dry for TEM imaging.

2.8 DOX loading SPION-loaded LTSL using the pH-gradient remote loading method

DOX was loaded into liposomes using a pH-gradient remote loading method. Following buffer exchange of the external buffer to HBS, the liposomes were incubated with DOX at DOX-to-
160 phospholipid molar ratio of 1:20 at 37 °C for 1.5 h. After incubation, liposomes were purified from unencapsulated DOX by SEC as described above. To quantify DOX encapsulation efficiency (DOX EE), liposomes before and after purification were diluted to the same lipid concentration and then solubilized by Triton X-100 to release encapsulated DOX. A final

concentration of 0.1 v/v % Triton X-100 was used, which corresponds to a phospholipid-to-
detergent molar ratio of 1:20, sufficient to ensure complete solubilization of liposomes [26].
DOX fluorescence intensity was measured using microplate reader with excitation and
emission wavelength of 485 nm and 590 nm, respectively. The concentration of DOX in the
wells were within the linear region. DOX EE was then calculated by comparing the
fluorescence intensity ($I(t)$) of the samples before and after purification:

$$DOX\ EE = \frac{I(t)\ after\ purification}{I(t)\ before\ purification}$$

2.9 Statistical analysis

Student's unpaired two-tailed t-test and one-way analysis of variance (ANOVA) followed by
Fisher's least significant difference (LSD) test were used to assess statistical significance
between group means [27,28]. All analyses were performed, with the significance level α of
0.05, using GraphPad Prism 7.0 (GraphPad Software Inc., CA, US).

3 Results

3.1 SPION precipitates in the presence of high-salt containing media and PEG-lipid

To form SPION-loaded LTSL (mLTSL10) by nanoprecipitation, a water-miscible organic phase is to be injected into the aqueous phase. Ethanol was used to dissolve the LTSL10 lipids (DPPC/MSPC/DSPE-PEG₂₀₀₀, 80/10/10 molar ratio) [21]. Tetrahydrofuran (THF) is miscible with both water and ethanol, and able to solubilize SPION, therefore an ideal solvent for mLTSL10 preparation. To introduce SPION to the LTSL10 formulation, SPION could be added to either the lipid-containing ethanol phase or the aqueous phase. To investigate the metastability and solubility of SPION when dispersed in these conditions, 200 $\mu\text{g mL}^{-1}$ SPION in THF was dispersed in ethanol, DW, $(\text{NH}_4)_2\text{SO}_4$ solution and HBS, with a final THF volume fraction of 1 v/v % (**Supplementary Figure S1a**). Although SPION was insoluble in ethanol and aqueous solution alone, it was metastable when dispersed in THF/ethanol and THF/DW with overnight stability. However, in the presence of salt ($(\text{NH}_4)_2\text{SO}_4$ and HBS), SPION precipitated rapidly and completely settled overnight. While SPION can be dispersed in THF/DW, the use of DW as an aqueous phase for nanoprecipitation is not desirable due to the high dispersity of the resultant vesicles [18,29]. In fact, HBS and $(\text{NH}_4)_2\text{SO}_4$ were the preferred aqueous phase for their relevance with biological and drug loading applications. Therefore, SPION was dispersed in the organic phase of THF/ethanol along with the lipids. Hereinafter, THF/ethanol was used as the organic phase and the volume fraction of THF in ethanol is implied by “% THF”.

Subsequently, mLTSL10 mixture comprising 200 $\mu\text{g mL}^{-1}$ SPION and 10 mM LTSL10 lipid was dispersed in 1% THF (**Supplementary Figure S1b**). Unexpectedly, the SPION rapidly precipitated in the presence of the lipids. To identify the cause, SPION was mixed with the three lipid components of LTSL10 (8 mM DPPC, 1 mM MSPC and 1 mM DSPE-PEG₂₀₀₀)

respectively. Clearly, SPION remained metastable with DPPC and MSPC but was precipitated with DSPE-PEG₂₀₀₀. It was evident that the presence of DSPE-PEG₂₀₀₀ disrupted the metastable SPION from the 1% THF solvent system. However, when SPION and DSPE-PEG₂₀₀₀ were dispersed in THF alone, the mixture remained stable (**Supplementary Figure S1c**). Therefore, it was hypothesized that the ratio between ethanol (to solubilize phospholipid) and THF (to solubilize SPION) could be optimized to achieve a stable dispersion of mLTSL10.

The stability of the mLTSL10 mixture in 0% to 100% THF was studied overnight (**Figure 1**). At 0% (absolute ethanol) to 40% THF, a decreasing amount of SPION was precipitated. At 60% and 80% THF, all components were soluble with overnight stability. In 100% THF, however, the mixture appeared turbid with the presence of precipitates. Therefore, the optimal volume fraction of THF should be greater than 40% and less than 100% THF.

3.2 THF affects LTSL10 size and dispersity but not membrane integrity

To determine the optimal THF volume fraction for mLTSL10 preparation, the effect of THF on the size and dispersity of LTSL10 was first investigated. The organic phase (0 – 75% THF) containing 10 mM LTSL10 was injected into the aqueous phase ((NH₄)₂SO₄ solution) at 60 °C with an aqueous-to-organic volume ratio (VR) of 3 (**Figure 2a, Supplementary Figure S2a**). One-way ANOVA was conducted to study the effect of %THF on the size and the dispersity of LTSL10. There were statistically significant differences in both size ($F_{4,17} = 162.2$, $p < 0.001$) and dispersity ($F_{4,17} = 4.934$, $p = 0.008$). LTSL10 size increased somewhat exponentially with THF, from about 80 – 100 nm in 0 – 40% THF, to about 230 nm in 50% – 60% THF, up to above 1000 nm in 75% THF. In contrast, LTSL10 dispersity increased moderately from 0.1 in 0 – 60% THF to 0.2 in 75% THF. Despite the variation in LTSL10 size with different THF volume fraction, LTSL10 remained uniform (dispersity < 0.2). To validate the membrane integrity of the LTSL10 prepared in the presence of THF, samples were remotely loaded with

DOX. Regardless of the %THF used for preparation, LTSL10 have DOX encapsulation efficiency (DOX EE) above 80% (83.86 ± 3.56 %; $n = 4$), indicating the presence of a transmembrane pH-gradient (necessary for DOX loading) thus the integrity of the membrane.

3.3 Uniform mLTSL10 successfully prepared with size dependent on injection volume ratio

After successful validation of LTSL10, SPION was included to optimize the preparation of mLTSL10. The organic phase (20 - 75% THF) containing 10 mM LTSL10 and $300 \mu\text{g mL}^{-1}$ SPION (equivalent to SPION-to-lipid ratio of $30 \mu\text{g } \mu\text{mol}^{-1}$ [22]) was injected into the aqueous phase ($(\text{NH}_4)_2\text{SO}_4$) at 60°C with an aqueous-to-organic volume ratio of 3 (**Figure 2b**, **Supplementary Figure S2b**). Expectedly, in 20 – 40% THF, due to the low stability of the mLTSL10 mixture, liposome size distributions were multimodal and highly dispersed (> 0.4); moreover, SPION precipitates could be observed. Therefore, one-way ANOVA was conducted to study the effect of %THF on the size and the dispersity of mLTSL10 prepared only in between 50 – 75% THF. There were statistically significant differences in both size ($F_{2,10} = 164.3$, $p < 0.001$) and dispersity ($F_{2,10} = 12.67$, $p = 0.002$). Both the liposome size and dispersity rose significantly with increasing THF volume fraction, from 50% THF (Z-average = 194.4 nm; dispersity = 0.107) to 60% THF (Z-average = 325.2 nm, $t_{10} = 3.947$, $p = 0.003$; dispersity = 0.182, $t_{10} = 2.348$, $p = 0.041$) and 75% THF (Z-average = 708.7 nm, $t_{10} = 18.12$, $p < 0.001$; dispersity = 0.241, $t_{10} = 4.879$, $p < 0.001$). Intriguingly, dispersity reached a local minimum of around 0.1 at 50% THF, where uniform mLTSL10 was obtained. Thus, 50% THF was deemed the optimal solvent condition to nanoprecipitate mLTSL10.

Once the formulation parameters were optimized, liposome size can be varied simply by changing the aqueous-to-organic volume ratio (VR) [18]. When VR was increased from 3 to 3.5, mLTSL10 size decreased from 194.4 ± 28.2 nm (dispersity = 0.107 ± 0.041 , $n = 8$) to 91.8

± 8.0 nm (dispersity = 0.091 ± 0.033 , $n = 5$) (**Supplementary Figure S3**). The changes in size was statistically significant ($t_{14} = 6.113$, $p < 0.001$) but insignificant for dispersity ($t_{14} = 1.023$, $p > 0.05$). Representative correlograms and cumulant fits of the intensity correlation function were provided (**Supplementary Figure S4**). Further increase of VR to 4 – 6 resulted in smaller (< 100 nm) but more dispersed (> 0.2) mLTSL10. This could be attributed to higher membrane curvature of smaller liposomes, resulting in greater membrane distortion by SPION and heterogeneous populations [9,30]. In conclusion, uniformly distributed mLTSL10 can be prepared using 50% THF, with two available sizes: 100 nm at VR of 3.5 and 200 nm at VR of 3. The zeta potential of the optimised mLTSL10 was -7.83 ± 0.806 ($n = 6$). Zeta potential of other conditions (20 – 75% THF) ranges between -10 to -7 mV, without major differences.

3.4 SPION loading affects liposome dispersity without affecting membrane integrity

In an attempt to maximize the SPION loading into mLTSL10, the organic phase (40 - 60% THF) containing 10 mM LTSL10 and 0 - 500 $\mu\text{g mL}^{-1}$ SPION (SPION-to-lipid ratio of 0 – 50, $\mu\text{g } \mu\text{mol}^{-1}$) was injected into the aqueous phase ($(\text{NH}_4)_2\text{SO}_4$) at 60 °C with an aqueous-to-organic volume ratio (VR) of 3 and 3.5 (**Figure 3**). It was expected that as the loading of SPION exceeds a certain threshold limit, SPION and LTSL10 can no longer self-assemble uniformly, larger and more dispersed samples would be formed.

Using the optimal solvent condition of 50% THF, for large LTSL10 (VR of 3), SPION-to-lipid ratio can reach up to 50 $\mu\text{g}/\mu\text{mol}$ with dispersity remaining < 0.2 . Interestingly, less amount of SPION (up to SPION-to-lipid ratio of 40 $\mu\text{g}/\mu\text{mol}$) was tolerated by the small mLTSL10 (VR of 3.5), as the dispersity increased to 0.2. Determined by one-way ANOVA, SPION concentration has statistically insignificant effect on mLTSL10 size for both large (VR of 3; $F_{2,11} = 0.078$, $p > 0.05$) and small mLTSL10 (VR of 3.5; $F_{4,20} = 2.822$, $p > 0.05$). On the other

hand, while there was insignificant effect on larger mLTSL10 dispersity ($F_{2,11} = 1.577$, $p > 0.05$), the effect on small mLTSL10 dispersity was significant ($F_{4,20} = 4.563$, $p = 0.009$).

At 40% THF where SPION are not well solubilized, mLTSL10 become dispersed as low as
275 SPION-to-lipid ratio of 15 $\mu\text{g}/\mu\text{mol}$, affirming that self-assembly of mLTSL10 in 40% THF is unfavorable. On the other hand, despite greater solubility of SPION in 60% THF, mLTSL10 have higher dispersity compared to those prepared in 50% THF, which may be attributed to the unfavorable condition for formation of liposome *per se* in high concentration of THF. Considering the desirable size and dispersity of the resultant mLTSL10, the optimal conditions
280 for preparing mLTSL10 were using 50% THF, with SPION-to-lipid ratio of 30 $\mu\text{g}/\mu\text{mol}$ and VR of 3.5.

The stability and membrane integrity of the optimized mLTSL10 was then characterized. Control experiments using only SPION without LTSL10 lipids were performed to validate the preparation processes. Initially, freshly prepared mLTSL10 after injection and annealing, were
285 left overnight in ambient conditions without SEC purification; despite noticeable reduction in volume due to evaporation of THF, the solution remained clear and disperse (**Figure 4a**). In contrast, under the same conditions in the absence of LTSL10 lipids, the samples were unstable (**Supplementary Figure S5a**). SPION precipitated at the wall and the bottom of the container, which also agreed with the low solubility of SPION in the presence of $(\text{NH}_4)_2\text{SO}_4$. This
290 suggested that SPION have interacted with the LTSL10 lipids, presumably either embedded into the lipid bilayer or formed micelles, resulting in greater dispersion stability. To remove free SPION, freshly prepared mLTSL10 was purified by SEC. mLTSL10 passed through the column at the expected elute volume for liposomes and was collected as a clear, brownish solution (**Figure 4b, 4c**). In contrast, SPION alone could not be eluted and was trapped in the
295 frit at the top of the SEC column (**Supplementary Figure S5b**), which further suggested that SPION and LTSL10 liposomes eluted as one population. Then, SPION EE of purified

mLTSL10 was characterized by AAS (**Figure 4d**). Large 200 nm mLTSL10 had a mean SPION EE of 85.85%, significantly greater than small 100 nm mLTSL10 of 60.77% ($t_{10} = 5.83$, $p < 0.001$). Liposomes of larger size have a lower surface curvature to accommodate SPION, which may explain the higher loading capacity and thus lower dispersity of larger mLTSL10 prepared in 50% THF [9,30]. Finally, to assess membrane integrity and drug loading capability, mLTSL10 were remotely loaded with DOX. As expected, DOX EE of all samples (0 – 40 $\mu\text{g}/\mu\text{mol}$ SPION-to-lipid ratio), were above 80% (**Figure 4e**). One-way ANOVA showed that the amount of SPION has no significant effect on the DOX EE ($F_{3,9} = 0.5386$, $p > 0.05$).

3.5 mLTSL10 Characterization

The mean phase transition temperatures of LTSL10 and mLTSL10, defined as the onset temperature of the melting peak characterized by DSC, were 41.55 °C and 41.87 °C respectively, (**Figure 5a, 5b**). The increased transition peak height of mLTSL10, suggests that the fluid LTSL10 membranes were stabilized by the embedded SPION. Although the phase transition temperature increased by 0.3 °C, it remained within the range of mild hyperthermia (40 – 42 °C) for thermosensitive release [2].

Representative TEM images showed that SPION have an iron core size of 4 – 5 nm, in agreement with our previous characterization [22], which are smaller than the reported maximum SPION diameter of 6.5 nm for embedding into lipid bilayers (**Figure 6a**) [31]. Particles of similar size and morphology to SPION were observed in the TEM micrographs of mLTSL10 (**Figure 6b**). SPION were evenly distributed within the liposomes, which can be attributed to the two-dimensional projection and flattening of spherical liposomes, indicating the embedment of SPION into the LTSL10 lipid bilayer. Only a trivial quantity of individual SPION and no irregularly shaped agglomerate (as observed in free SPION) were observed,

320 confirming the successful purification of unencapsulated and the effective embedment of SPION into LTSL10.

4 Discussion

To date, majority of magnetoliposome have been prepared by batch methods in combination
325 with downsizing techniques of extrusion [7,10,11,22] or sonication [4,8,9,14]. Indeed, due to
the robustness of downsizing, there are little or no limitations on the quality of the preformed
liposomes; large, heterogeneous, multilamellar vesicles can be processed into small,
unilamellar vesicles. However, both techniques have limited scalability and come with their
own disadvantages; sonication may degrade or contaminate the sample, while extrusion may
330 suffer from high product losses [32]. In contrast, nanoprecipitation is a self-assembly process
which homogeneous unilamellar liposomes are formed directly. There is no need for
downsizing and homogenization, in turn the liposome quality is governed by the formulation
and processing parameters.

To formulate thermosensitive magnetoliposome mLTSL10 via nanoprecipitation, the
335 formulation parameters must be first designed and optimized carefully to ensure all
components can self-assemble into vesicles homogeneously. First, the thermosensitive
formulation LTSL10 was selected, as we previously optimized for nanoprecipitation
preparation [21]. Since the self-assembled liposomes are inevitably exposed to organic solvents
during the nanoprecipitation, they will be prone to ethanol-induced interdigitation [33]. In
340 contrast with typical LTSL formulations that contain about 4 – 5 mol% DSPE-PEG₂₀₀₀, DSPE-
PEG₂₀₀₀ was increased to 10 mol% in LTSL10 to avoid the interdigitated gel phase [21].

Next, the solvent phases were optimized to ensure all components are well-solubilized and to
prevent premature precipitation. Ammonium sulfate solution was selected as the aqueous phase
to enable DOX remote loading; ethanol and THF were used to dissolve lipids and SPION,
345 respectively. THF has been an attractive organic solvent given its ability to dissolve
hydrophobic substances while being water miscible. THF was commonly employed in the

nanoprecipitation of inorganic and polymer nanoparticles [34–37]. Although SPION was metastable in 1% THF (in 99% ethanol), the presence of DSPE-PEG₂₀₀₀ rapidly disrupted the system. The relatively high solubility of DSPE-PEG₂₀₀₀ in THF suggested that the surface-
350 bounded THF could be displaced from the SPION, exposing them to ethanol resulting in precipitation. Conversely, DPPC and MSPC did not disrupt the SPION in 1% THF, in agreement with the relatively low solubility of DPPC and MSPC in THF. Consequently, the volume fraction of THF was inevitably increased to 50% THF for a stable mLTSL10 mixture, where uniform mLTSL10 could be prepared. Similarly, others have used at least 40% THF in
355 ethanol to prepare entrapped SPION in solid lipid nanoparticles [34] and conventional magnetoliposomes [35].

The effect of introducing THF in ethanol led to substantial increase in both size and dispersity for both LTSL10 and mLTSL10. Since self-assembly (via nanoprecipitation) is a spontaneous process that minimizes the molecular free energy, factors such as solubility and diffusivity of
360 individual components (lipids, SPION or solvents) in the system would all contribute to the resultant assembly's lowest energy state, hence the quality of the liposome population [16]. Others have observed that smaller polymeric nanoparticle sizes were obtained using solvents with greater diffusion coefficient in water [37,38]. The effect can be explained by the nanoprecipitation process, as solvents diffuse faster into water, solutes reach their critical
365 nucleation concentration earlier, providing less time for nuclei to grow in size, resulting in smaller nanoprecipitates [16]. Literature on the tertiary system of THF-ethanol-water were yet to be available; however, based on the data on the binary systems, the diffusion coefficient of ethanol-water is greater than that of THF-water [39,40]. Therefore, it may be reasoned that with increasing % THF in ethanol, the diffusion coefficient would decrease, which could
370 explain our observation that larger mLTSL10 were formed as volume fraction of THF increased.

Using lower concentration of THF is preferred; apart from forming dispersed mLTSL10 population, THF raises other concerns regarding scaling-up. High volatility and the ethereal smell of THF may be unpleasant for user to handle; moreover, THF is highly flammable and can decompose into explosive peroxide, posing safety hazards. Furthermore, THF limits the choice of material for scale-up production. Microfluidics, the manipulation of fluid in microscale channels, is an emerging technique for nanoprecipitation of liposomes and acceleration of their clinical translation [20]. Major advantages of microfluidics in nanoparticles synthesis includes excellent manipulation of fluids, high reproducibility, tunable nanoparticle size and the process is readily scalable by continuous production and parallelization [19]. Currently, owing to the advancement in microfabrication, many microfluidic devices are polymer-based (such as polydimethylsiloxane and cyclic olefin copolymer) for their low-cost and ease of fabrication but have limited compatibility towards strong organic solvents like THF [34,41]. In fact, ongoing research has been conducted to advance material fabrication and microfluidic capabilities, in turn accelerating the development and translation of products prepared by nanoprecipitation [41,42]. In this regard, in order to translate the batch injection preparation of mLTSL10 to the continuous, scalable microfluidics method, upcoming microfluidic devices will have to tolerate a minimum of 50% THF in ethanol.

Thus far, there are only few reports on the nanoprecipitation of magnetoliposomes. Kulkarni et al. presented the nanoprecipitation of SPION-loaded solid lipid nanoparticles (SLNs), comprising abundant hydrophobic core lipids of triglycerides or sterols (up to 97.5 mol%) to entrap SPION in the SLN core [34]. Nevertheless, 40% THF was still necessary to solubilize SPION in the initial lipid mixture. In comparison, Bixner and Reimhult used 100% THF to prepare conventional (non-PEGylated) magnetoliposome [35]. Both reported formulations are based on unsaturated phospholipid, which have high fluidity and great tolerance towards

interdigitation, thus suitable for preparation using nanoprecipitation. Although from the clinical translation point of view, unsaturated phospholipids are prone to oxidation and their low phase transition temperature can result in premature release at physiological temperature [43]. In comparison, mLTSL10 comprises saturated phospholipids and PEG-lipid, are designed based on the most clinically advanced LTSL formulation, ThermoDox®, which also offers triggered drug release capability. We carefully evaluated the effect of THF-ethanol binary solvent system on the mLTSL10 to attain the optimized condition of 50% THF, without the need of hydrophobic core lipids and avoided using excessive THF. Moreover, mLTSL10 was prepared in ammonium sulfate which enabled the remote loading of hydrophilic cargo, such as DOX. mLTSL10 is capable of co-encapsulation of hydrophobic SPION and hydrophilic drugs, which is unprecedented in previous reports.

It is important to note that between different nanoprecipitation techniques (e.g. solvent injection, microfluidics, cross-flow injection), the mechanism of liposome formation remains identical, thus the formulation parameters are readily transferable. However, processing parameters (e.g. volume ratio, mixing efficiency, flow rates) will be expected to vary according to the mixing conditions and efficiency of respective techniques [18]; as processing parameters of bench-scale preparation are also expected to differ from that of industrial scale [16]. Nonetheless, it remained promising and advantageous to prepare nanoparticles using nanoprecipitation for its simplicity and capability of scale-up production for accelerating clinical translations.

5 Conclusion

In summary, the presented results show that the nanoprecipitation technique successfully
420 enabled the loading of SPION into the low temperature-sensitive liposomal system, yielding
spherical, nano-sized homogeneous magneto-thermosensitive liposomes, mLTSL10. The
effect of the formulation parameters, solvent system and SPION concentration, were
investigated and optimized. Minimal amount of 50% THF was required to yield uniform and
stable mLTSL10. Thermosensitivity and membrane integrity were not affected by the inclusion
425 of SPION. The nanoprecipitation technique allows efficient SPION loading into liposomes and
eliminates the need for post processing such as extrusion or sonication. It is envisaged that in
combination with scalable nanoprecipitation platform such as microfluidics, the development
of mLTSL10 as a responsive drug delivery carrier will be further accelerated.

Conflicts of interest

430 There are no conflicts to declare.

Acknowledgment

This work was supported by the Prostate Cancer UK (Grant CDF12-002), and the Engineering
and Physical Sciences Research Council (EPSRC) (EP/M008657/1).

435 **References**

- [1] G.Kong, G.Anyarambhatla, W.P.Petros, R.D.Braun, O.M.Colvin, D.Needham,
M.W.Dewhirst, Efficacy of liposomes and hyperthermia in a human tumor xenograft
model: importance of triggered drug release., *Cancer Res.* 60 (2000) 6950–7.
- [2] D.Needham, G.Anyarambhatla, G.Kong, M.W.Dewhirst, A new temperature-sensitive
440 liposome for use with mild hyperthermia: Characterization and testing in a human tumor
xenograft model, *Cancer Res.* 60 (2000) 1197–1201.
- [3] Y.Dou, K.Hynynen, C.Allen, To heat or not to heat: Challenges with clinical translation
of thermosensitive liposomes, *J. Control. Release.* 249 (2017) 63–73.
- [4] Z.Al-Ahmady, N.Lozano, K.C.Mei, W.T.Al-Jamal, K.Kostarelos, Engineering
445 thermosensitive liposome-nanoparticle hybrids loaded with doxorubicin for heat-
triggered drug release, *Int. J. Pharm.* 514 (2016) 133–141.
- [5] N.Forbes, A.Pallaoro, N.O.Reich, J.A.Zasadzinski, Rapid, Reversible Release from
Thermosensitive Liposomes Triggered by Near-Infra-Red Light, *Part. Part. Syst.*
Charact. 31 (2014) 1158–1167.
- 450 [6] N.Forbes, J.E.Shin, M.Ogunyankin, J.A.Zasadzinski, Inside-outside self-assembly of
light-activated fast-release liposomes, *Phys. Chem. Chem. Phys.* 17 (2015) 15569–
15578.
- [7] J.-P.Fortin-Ripoche, M.S.Martina, F.Gazeau, C.Ménager, C.Wilhelm, J.-C.Bacri,
S.Lesieur, O.Clément, Magnetic Targeting of Magnetoliposomes to Solid Tumors with
455 MR Imaging Monitoring in Mice: Feasibility, *Radiology.* 239 (2006) 415–424.
- [8] G.Béalle, R.DiCorato, J.Kolosnjaj-Tabi, V.Dupuis, O.Clément, F.Gazeau, C.Wilhelm,
C.Ménager, Ultra magnetic liposomes for MR imaging, targeting, and hyperthermia,

Langmuir. 28 (2012) 11834–11842.

- [9] R.Martínez-González, J.Estelrich, M.A.Busquets, Liposomes loaded with hydrophobic
460 iron oxide nanoparticles: Suitable T2 contrast agents for MRI, *Int. J. Mol. Sci.* 17 (2016)
1–14.
- [10] E.Amstad, J.Kohlbrecher, E.Müller, T.Schweizer, M.Textor, E.Reimhult, Triggered
release from liposomes through magnetic actuation of iron oxide nanoparticle containing
membranes, *Nano Lett.* 11 (2011) 1664–1670.
- 465 [11] Y.Guo, Y.Zhang, J.Ma, Q.Li, Y.Li, X.Zhou, D.Zhao, H.Song, Q.Chen, X.Zhu,
Light/magnetic hyperthermia triggered drug released from multi-functional thermo-
sensitive magnetoliposomes for precise cancer synergetic theranostics, *J. Control.*
Release. 272 (2018) 145–158.
- [12] A.C.Silva, T.R.Oliveira, J.B.Mamani, S.M.F.Malheiros, L.Malavolta, L.F.Pavon,
470 T.T.Sibov, E.Amaro, A.Tannús, E.L.G.Vidoto, M.J.Martins, R.S.Santos, L.F.Gamarra,
Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in
glioma treatment., *Int. J. Nanomedicine.* 6 (2011) 591–603.
- [13] B.Le, M.Shinkai, T.Kitade, H.Honda, J.Yoshida, T.Wakabayashi, T.Kobayashi,
Preparation of tumor-specific magnetoliposomes and their application for hyperthermia,
475 *J. Chem. Eng. Japan.* 34 (2001) 66–72.
- [14] Y.Chen, A.Bose, G.D.Bothun, Controlled Release from Bilayer- Decorated
Magnetoliposomes via Electromagnetic Heating, *ACS Nano.* 4 (2010) 3215–3221.
- [15] S.Hua, M.B.C.deMatos, J.M.Metselaar, G.Storm, Current Trends and Challenges in the
Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational
480 Development and Commercialization, *Front. Pharmacol.* 9:790 (2018).

- [16] C.J.Martínez Rivas, M.Tarhini, W.Badri, K.Miladi, H.Greige-Gerges, Q.A.Nazari, S.A.Galindo Rodríguez, R.Á.Román, H.Fessi, A.Elaissari, Nanoprecipitation process: From encapsulation to drug delivery, *Int. J. Pharm.* 532 (2017) 66–81.
- 485 [17] L.Capretto, D.Carugo, S.Mazzitelli, C.Nastruzzi, X.Zhang, Microfluidic and lab-on-a-chip preparation routes for organic nanoparticles and vesicular systems for nanomedicine applications, *Adv. Drug Deliv. Rev.* 65 (2013) 1496–1532.
- [18] C.C.L.Cheung, W.T.Al-Jamal, Sterically stabilized liposomes production using staggered herringbone micromixer: Effect of lipid composition and PEG-lipid content, *Int. J. Pharm.* 566 (2019) 687–696.
- 490 [19] J.Ma, S.M.Y.Lee, C.Yi, C.W.Li, Controllable synthesis of functional nanoparticles by microfluidic platforms for biomedical applications-a review, *Lab Chip.* 17 (2017) 209–226.
- [20] P.M.Valencia, O.C.Farokhzad, R.Karnik, R.Langer, Microfluidic technologies for accelerating the clinical translation of nanoparticles, *Nat. Nanotechnol.* 7 (2012) 623–
- 495 629.
- [21] C.C.L.Cheung, G.Ma, A.Ruiz, W.T.Al-Jamal, Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes, *J. Vis. Exp.* 157 (2020) e60907.
- [22] N.Kostevšek, C.C.L.Cheung, I.Serša, M.E.Kreft, I.Monaco, M.Comes Franchini, J.Vidmar, W.T.Al-Jamal, Magneto-Liposomes as MRI Contrast Agents: A Systematic
- 500 Study of Different Liposomal Formulations, *Nanomaterials.* 10 (2020) 889.
- [23] X.Teng, H.Yang, Effects of surfactants and synthetic conditions on the sizes and self-assembly of monodisperse iron oxide nanoparticles, *J. Mater. Chem.* 14 (2004) 774–779.

- [24] T.P.Niebel, F.J.Heiligttag, J.Kind, M.Zanini, A.Lauria, M.Niederberger, A.R.Studart,
505 Multifunctional microparticles with uniform magnetic coatings and tunable surface
chemistry, RSC Adv. 4 (2014) 62483–62491.
- [25] R.F.T.Stepto, Dispersity in polymer science (IUPAC Recommendations 2009), Pure
Appl. Chem. 81 (2009) 351–353.
- [26] O.López, A.DeLa Maza, L.Coderch, C.López-Iglesias, E.Wehrli, J.L.Parra, Direct
510 formation of mixed micelles in the solubilization of phospholipid liposomes by Triton
X-100, FEBS Lett. 426 (1998) 314–318.
- [27] K.J.Rothman, No adjustments are needed for multiple comparisons., Epidemiology. 1
(1990) 43–6.
- [28] D.J.Saville, Multiple Comparison Procedures: The Practical Solution, Am. Stat. 44
515 (1990) 174.
- [29] M.A.Obeid, I.Khadra, A.B.Mullen, R.J.Tate, V.A.Ferro, The effects of hydration media
on the characteristics of non-ionic surfactant vesicles (NISV) prepared by microfluidics,
Int. J. Pharm. 516 (2017) 52–60.
- [30] C.Bonnaud, C.A.Monnier, D.Demurtas, C.Jud, D.Vanhecke, X.Montet, R.Hovius,
520 M.Lattuada, B.Rothen-Rutishauser, A.Petri-Fink, Insertion of nanoparticle clusters into
vesicle bilayers, ACS Nano. 8 (2014) 3451–3460.
- [31] H.S.Wi, K.Lee, H.Kyu Pak, Interfacial energy consideration in the organization of a
quantum dot–lipid mixed system, J. Phys. Condens. Matter. 20 (2008) 494211.
- [32] A.Wagner, K.Vorauer-Uhl, Liposome Technology for Industrial Purposes, J. Drug
525 Deliv. 2011 (2011) 1–9.
- [33] M.Patra, E.Salonen, E.Terama, I.Vattulainen, R.Faller, B.W.Lee, J.Holopainen,

M.Karttunen, Under the influence of alcohol: The effect of ethanol and methanol on lipid bilayers, *Biophys. J.* 90 (2006) 1121–1135.

- 530 [34] J.A.Kulkarni, Y.Y.C.Tam, S.Chen, Y.K.Tam, J.Zaifman, P.R.Cullis, S.Biswas, Rapid synthesis of lipid nanoparticles containing hydrophobic inorganic nanoparticles, *Nanoscale*. 9 (2017) 13600–13609.
- [35] O.Bixner, E.Reimhult, Controlled magnetosomes: Embedding of magnetic nanoparticles into membranes of monodisperse lipid vesicles, *J. Colloid Interface Sci.* 466 (2016) 62–71.
- 535 [36] P.M.Valencia, P.A.Basto, L.Zhang, M.Rhee, R.Langer, O.C.Farokhzad, R.Karnik, Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing, *ACS Nano*. 4 (2010) 1671–1679.
- [37] W.Huang, C.Zhang, Tuning the Size of Poly(lactic-co-glycolic Acid) (PLGA) Nanoparticles Fabricated by Nanoprecipitation, *Biotechnol. J.* 13 (2018) 1700203.
- 540 [38] P.Legrand, S.Lesieur, A.Bochot, R.Gref, W.Raatjes, G.Barratt, C.Vauthier, Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation, *Int. J. Pharm.* 344 (2007) 33–43.
- 545 [39] D.G.Leaist, K.MacEwan, A.Stefan, M.Zamari, Binary mutual diffusion coefficients of aqueous cyclic ethers at 25 °C. Tetrahydrofuran, 1,3-dioxolane, 1,4-dioxane, 1,3-dioxane, tetrahydropyran, and trioxane, *J. Chem. Eng. Data*. 45 (2000) 815–818.
- [40] S.Páñez, G.Guevara-Carrion, H.Hasse, J.Vrabec, Mutual diffusion in the ternary mixture of water + methanol + ethanol and its binary subsystems, *Phys. Chem. Chem. Phys.* 15 (2013) 3985.
- [41] X.Hou, Y.S.Zhang, G.T.Santiago, M.M.Alvarez, J.Ribas, S.J.Jonas, P.S.Weiss,

- 550 A.M.Andrews, J.Aizenberg, A.Khademhosseini, Interplay between materials and microfluidics, *Nat. Rev. Mater.* 2 (2017) 17016.
- [42] S.Goyal, A.E.Economou, T.Papadopoulos, E.M.Horstman, G.G.Z.Zhang, Y.Gong, P.J.A.Kenis, Solvent compatible microfluidic platforms for pharmaceutical solid form screening, *RSC Adv.* 6 (2016) 13286–13296.
- 555 [43] M.K.Yeh, H.I.Chang, Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacy, *Int. J. Nanomedicine.* 7 (2011) 49.

Figures

560 **Figure 1. Solubility of SPION and LTSL10 lipid in THF/ethanol binary solvent mixtures.**

Photos of $200\ \mu\text{g mL}^{-1}$ SPION with 10 mM LTSL10 dispersed in ethanol with (left to right) 0, 20, 40, 60, 80, 100% THF at 20 °C.

565 **Figure 2. Effect of THF volume fraction on LTSL10 and mLTSL10 size and dispersity.**

(a) 10 mM LTSL10 and (b) 10 mM LTSL10 containing 300 µg mL⁻¹ SPION, dispersed in 0 – 75% THF, were injected into (NH₄)₂SO₄ with volume ratio of 3. Data are mean ± SD (n = 2 – 7).

Figure 3. Effect of SPION concentration and %THF on mLTSL10 size and dispersity. (a) Z-average diameter and (b) dispersity of mLTSL10 with SPION-to-lipid ratio of 0 – 50 ($\mu\text{g}/\mu\text{mol}$), dispersed in 40 – 60 % THF, were injected into $(\text{NH}_4)_2\text{SO}_4$ with a volume ratio of 3 (or 3.5). Data are mean $\pm$ SD ($n = 2 - 7$). Inset are representative photo of mLTSL10 with SPION-to-lipid ratio of 0 – 40 ($\mu\text{g}/\mu\text{mol}$)

Figure 4. mLTSL10 preparation and characterization (a-c) mLTSL10 loaded with SPION-to-lipid ratio of 30 ($\mu\text{g}/\mu\text{mol}$), dispersed in 50% THF, injected with a volume ratio of 3.5. (a) mLTSL10 remained disperse at 20 °C overnight without purification. (b) mLTSL10 passing through SEC column during purification. Red box indicates the location of the mLTSL10. (c) Representative photo of collected mLTSL10 after SEC purification. (d) SPION encapsulation efficiency of mLTSL10 prepared in 50% THF with injection volume ratio of 3 and 3.5. ($n = 4 - 7$). Two-tailed unpaired t -test; ***, $p < 0.001$. (e) DOX encapsulation efficiency of mLTSL10 dispersed in 50% THF with injection volume ratio of 3.5 ($n = 2 - 7$). Inset is representative photo of purified mLTSL10 after DOX remote loading. Data are mean $\pm$ SD.

Figure 5. Thermal analysis of LTSL10 and mLTSL10. (a) Thermographs and (b) Onset phase transition temperature of LTSL10 and mLTSL10 characterized by DSC ($n = 3 - 9$).

590 Dotted lines as tangent of the point of maximum slope, are added as a visual aid of the onset phase transition temperature (x-intercept of the tangent line). Two-tailed unpaired t -test; *, $p < 0.05$. Data are mean $\pm$ SD.

595 **Figure 6.** TEM micrographs of (a) SPION in THF, and (b) optimized mLTSL10 (dispersed in 50% THF, injection volume ratio of 3.5). Scale bars are 50 nm.